219 related articles for article (PubMed ID: 19735093)
41. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease.
Cookson MR
Nat Rev Neurosci; 2010 Dec; 11(12):791-7. PubMed ID: 21088684
[TBL] [Abstract][Full Text] [Related]
42. Outcome of bilateral deep brain subthalamic stimulation in patients carrying the R1441G mutation in the LRRK2 dardarin gene.
Gómez-Esteban JC; Lezcano E; Zarranz JJ; González C; Bilbao G; Lambarri I; Rodríguez O; Garibi J
Neurosurgery; 2008 Apr; 62(4):857-62; discussion 862-3. PubMed ID: 18496192
[TBL] [Abstract][Full Text] [Related]
43. LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions.
Huang Y; Song YJ; Murphy K; Holton JL; Lashley T; Revesz T; Gai WP; Halliday GM
Acta Neuropathol; 2008 Dec; 116(6):639-46. PubMed ID: 18936941
[TBL] [Abstract][Full Text] [Related]
44. Lack of exacerbation of neurodegeneration in a double transgenic mouse model of mutant LRRK2 and tau.
Mikhail F; Calingasan N; Parolari L; Subramanian A; Yang L; Flint Beal M
Hum Mol Genet; 2015 Jun; 24(12):3545-56. PubMed ID: 25804954
[TBL] [Abstract][Full Text] [Related]
45. Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease.
Tan EK; Skipper L; Chua E; Wong MC; Pavanni R; Bonnard C; Kolatkar P; Liu JJ
Mov Disord; 2006 Jul; 21(7):997-1001. PubMed ID: 16602113
[TBL] [Abstract][Full Text] [Related]
46. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
[TBL] [Abstract][Full Text] [Related]
47. Progress in defining the premotor phase of Parkinson's disease.
Tolosa E; Pont-Sunyer C
J Neurol Sci; 2011 Nov; 310(1-2):4-8. PubMed ID: 21679972
[TBL] [Abstract][Full Text] [Related]
48. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity.
Gillardon F; Schmid R; Draheim H
Neuroscience; 2012 Apr; 208():41-8. PubMed ID: 22342962
[TBL] [Abstract][Full Text] [Related]
49. Emerging pathways in genetic Parkinson's disease: tangles, Lewy bodies and LRRK2.
Devine MJ; Lewis PA
FEBS J; 2008 Dec; 275(23):5748-57. PubMed ID: 19021752
[TBL] [Abstract][Full Text] [Related]
50. Clinical genetics of Parkinson's disease and related disorders.
Wider C; Wszolek ZK
Parkinsonism Relat Disord; 2007; 13 Suppl 3():S229-32. PubMed ID: 18267241
[TBL] [Abstract][Full Text] [Related]
51. Leucine-rich repeat kinase 2 colocalizes with alpha-synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies.
Perry G; Zhu X; Babar AK; Siedlak SL; Yang Q; Ito G; Iwatsubo T; Smith MA; Chen SG
Neurodegener Dis; 2008; 5(3-4):222-4. PubMed ID: 18322396
[TBL] [Abstract][Full Text] [Related]
52. Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients.
Floris G; Cannas A; Solla P; Murru MR; Tranquilli S; Corongiu D; Rolesu M; Cuccu S; Sardu C; Marrosu F; Marrosu MG
Parkinsonism Relat Disord; 2009 May; 15(4):277-80. PubMed ID: 18805725
[TBL] [Abstract][Full Text] [Related]
53. The parkinson's disease-associated LRRK2 mutation R1441G inhibits neuronal differentiation of neural stem cells.
Bahnassawy L; Nicklas S; Palm T; Menzl I; Birzele F; Gillardon F; Schwamborn JC
Stem Cells Dev; 2013 Sep; 22(18):2487-96. PubMed ID: 23600457
[TBL] [Abstract][Full Text] [Related]
54. Comprehensive screening of a North American Parkinson's disease cohort for LRRK2 mutation.
Johnson J; Paisán-Ruíz C; Lopez G; Crews C; Britton A; Malkani R; Evans EW; McInerney-Leo A; Jain S; Nussbaum RL; Foote KD; Mandel RJ; Crawley A; Reimsnider S; Fernandez HH; Okun MS; Gwinn-Hardy K; Singleton AB
Neurodegener Dis; 2007; 4(5):386-91. PubMed ID: 17622782
[TBL] [Abstract][Full Text] [Related]
55. Screening for LRRK2 mutations in patients with Parkinson's disease in Russia: identification of a novel LRRK2 variant.
Pchelina SN; Yakimovskii AF; Emelyanov AK; Ivanova ON; Schwarzman AL; Singleton AB
Eur J Neurol; 2008 Jul; 15(7):692-6. PubMed ID: 18435766
[TBL] [Abstract][Full Text] [Related]
56. Genetics of Parkinson's disease: a review of SNCA and LRRK2.
Konno T; Siuda J; Wszolek ZK
Wiad Lek; 2016; 69(3 Pt 1):328-32. PubMed ID: 27486710
[TBL] [Abstract][Full Text] [Related]
57. Lrrk2 and chronic inflammation are linked to pallido-ponto-nigral degeneration caused by the N279K tau mutation.
Miklossy J; Qing H; Guo JP; Yu S; Wszolek ZK; Calne D; McGeer EG; McGeer PL
Acta Neuropathol; 2007 Sep; 114(3):243-54. PubMed ID: 17639429
[TBL] [Abstract][Full Text] [Related]
58. The biology and pathobiology of LRRK2: implications for Parkinson's disease.
Moore DJ
Parkinsonism Relat Disord; 2008; 14 Suppl 2():S92-8. PubMed ID: 18602856
[TBL] [Abstract][Full Text] [Related]
59. Leucine-rich repeat kinase 2 (LRRK2) mutations in a Swedish Parkinson cohort and a healthy nonagenarian.
Carmine Belin A; Westerlund M; Sydow O; Lundströmer K; Håkansson A; Nissbrandt H; Olson L; Galter D
Mov Disord; 2006 Oct; 21(10):1731-4. PubMed ID: 16817197
[TBL] [Abstract][Full Text] [Related]
60. LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease.
Infante J; Rodríguez E; Combarros O; Mateo I; Fontalba A; Pascual J; Oterino A; Polo JM; Leno C; Berciano J
Neurosci Lett; 2006 Mar; 395(3):224-6. PubMed ID: 16298482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
